Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Olema Pharmaceuticals (OLMA – Research Report). The associated price target remains the same with $27.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sam Slutsky’s rating is based on Olema Pharmaceuticals’ promising development pipeline, particularly in the treatment of ER+ breast cancer. The company has shown progress with its Phase 1b/2 study of palazestrant (OP-1250) in combination with Kisqali, which targets advanced ER+ breast cancer patients. The anticipation of mature data from this study, expected to be shared at a medical meeting in 2025, adds to the positive outlook.
Additionally, Olema’s strategic plans for 2025, including the initiation of the Phase 3 OPERA-02 trial, further support the Buy rating. This trial will test the efficacy of palazestrant combined with Kisqali for first-line ER+ breast cancer treatment. The company’s focus on execution and upcoming data releases, which could impact their development pipeline, are key factors in the Buy recommendation.